Publisert 10.03.2021

EU Invest Horizon - Series A process Regenics

EU Invest Horizon - Series A program.

Regenics has been selected for the Invest Horizon program in EU as a "deep tech" company. The criterion for selection is

1) Made seed investment

2) Obtained at least 2.5 m Euro in series A funding

3) Is within the EU «deep tech» areas, which correlates to  «Engaged in the field of deep tech and raising at least EUR 2.5M in Series A funding»

Regenics is nominated to the program. Thus, not an investment selection, but a pre-program to qualify for Series A investment from EU investors. Regenics also holds a "Seal of Excellence" certificate from EU (SoE) issued to 10-15% of the best SMEs in the EU (who apply for EU public funding).

Regenics was awarded in 2020  17.3 mil NOK from 2020-2023 from the EU funded BlueBio Cofund program that together with the Seal of Exclence rating,  serves as external quality review of the business case.  

For more info on EUs Invest Horizon 

For more info on EU "Deep Tech" cathegorization of companies

 

Regenics AS have developed clinical proof of efficacy and safety  in human 2 degree burn wounds for our products Collex® and Vernex®.

The procudts are beeing developed as class III devices. WoundClear® is developed as a BLA/EU CP biotech drug.